Status:
RECRUITING
Neuroimmunology Registry and Biobank
Lead Sponsor:
Charite University, Berlin, Germany
Collaborating Sponsors:
University of Ulm
Conditions:
Encephalopathy
Psychosis
Eligibility:
All Genders
Brief Summary
A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases. This raises the question of whether these antibodies are disease-specif...
Detailed Description
The hypothesis that autoimmunity is a driving force behind many neurological diseases has become an established view in adult and pediatric neurology. This is particularly true for diseases of the cen...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Differential diagnosis: suspected neuroimmunological disease in which a lumbar puncture is indicated for further diagnosis and treatment decision
- Individuals with unclear clinical diagnosis where additional CSF is to be collected for isolation of B cells and production of monoclonal antibodies. The clinical condition of the patients and his/her compliance have to allow an extra 2-3 ml of CSF to be collected.
- Age: all age groups
- Gender: patients of both sexes will be included
- Exclusion criteria:
- \[1\] Withdrawal of consent
Exclusion
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2031
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06958341
Start Date
February 1 2021
End Date
July 1 2031
Last Update
May 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, Germany, 13353
2
Universität Ulm
Ulm, Germany, 89081